Cargando…
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has re...
Autores principales: | Bajpai, Richa, Sharma, Aditi, Achreja, Abhinav, Edgar, Claudia L., Wei, Changyong, Siddiqa, Arusha A., Gupta, Vikas A., Matulis, Shannon M., McBrayer, Samuel K., Mittal, Anjali, Rupji, Manali, Barwick, Benjamin G., Lonial, Sagar, Nooka, Ajay K., Boise, Lawrence H., Nagrath, Deepak, Shanmugam, Mala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060223/ https://www.ncbi.nlm.nih.gov/pubmed/32144272 http://dx.doi.org/10.1038/s41467-020-15051-z |
Ejemplares similares
-
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015) -
Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022) -
Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015) -
Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022) -
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)